Get the Stockscreener App
27.43
0.15%
0.055
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $27.43, with a volume of 11.87M.
It is up +0.15% in the last 24 hours and up +6.86% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$27.37
Open:
$27.44
24h Volume:
11.87M
Relative Volume:
0.23
Market Cap:
$155.93B
Revenue:
$62.58B
Net Income/Loss:
$7.79B
P/E Ratio:
20.24
EPS:
1.3551
Net Cash Flow:
$10.38B
1W Performance:
-1.15%
1M Performance:
+6.86%
6M Performance:
+9.33%
1Y Performance:
+7.24%
1-Day Range:
$27.20
$27.48
1-Week Range:
$27.20
$27.94
52-Week Range:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.43 | 155.62B | 62.58B | 7.79B | 10.38B | 1.3551 |
|
LLY
Lilly Eli Co
|
1,018.40 | 977.37B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
244.04 | 586.40B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.78 | 411.55B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
208.32 | 324.75B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
165.27 | 317.08B | 54.72B | 14.02B | 15.32B | 7.1855 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer (PFE) Experiences Mixed Options Sentiment Amid Downgrade - GuruFocus
Is There 25% Downside For Pfizer Stock? - Forbes
Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study - TipRanks
Pfizer: Recovery Not Over, Battered Valuation Discounts Turnaround Game (NYSE:PFE) - Seeking Alpha
Pfizer Colorectal Cancer Trial Win Adds Weight To Oncology Turnaround Story - Yahoo Finance
Pfizer (PFE) Valuation Check After Recent Share Price Rebound And Mixed Earnings Signals - Yahoo Finance Singapore
Sleep Aids Market 2026-2035 Top Key Playres: Pfizer (US), - openPR.com
Essex Financial Services Inc. Trims Stock Holdings in Pfizer Inc. $PFE - MarketBeat
CenterBook Partners LP Has $12.65 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Advisors Capital Management LLC Purchases 260,742 Shares of Pfizer Inc. $PFE - MarketBeat
Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider - GlobeNewswire Inc.
Skandinaviska Enskilda Banken AB publ Trims Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer - Business Wire
Pfizer: The Rebound Looks Unsustainable (NYSE:PFE) - Seeking Alpha
Pfizer’s Braftovi Scores Again In Confirmatory Colorectal Cancer Trial - Citeline News & Insights
Mubadala Investment Co PJSC reports share stake in Pfizer, AbbVie, dissolves in Merck, Dell - marketscreener.com
Mubadala Investment Co Pjsc Reports Share Stake In Pfizer, Abbvie, Dissolves in Merck, Dell - TradingView
How Is The Market Feeling About Pfizer Inc? - Benzinga
Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer TrialPfizer (NYSE:PFE) - Benzinga
Pfizer's (PFE) Braftovi Shows Promise in Colorectal Cancer Trial - GuruFocus
Pfizer posts trial win for cancer therapy Braftovi (PFE:NYSE) - Seeking Alpha
Pfizer (PFE) Reports Positive Results from BREAKWATER Trial in m - GuruFocus
Pfizer Trial Updates Test Investor Views On Pipeline And Valuation - Yahoo Finance Singapore
Pfizer Inc. $PFE is PARK CIRCLE Co's 10th Largest Position - MarketBeat
Pfizer's Braftovi regimen improves progression-free survival in metastatic colorectal cancer - marketscreener.com
Rothschild & Co Redburn Adjusts Price Target on Pfizer to $25 From $23, Maintains Neutral Rating - marketscreener.com
M&G PLC Lowers Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Shell Asset Management Co. Has $1.03 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Ovarian Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact - Barchart.com
Vanguard Group Inc. Has $13.61 Billion Stock Position in Pfizer Inc. $PFE - MarketBeat
PNC Financial Services Group Inc. Sells 223,165 Shares of Pfizer Inc. $PFE - MarketBeat
Bastion Asset Management Inc. Invests $2.38 Million in Pfizer Inc. $PFE - MarketBeat
Fifth Third Bancorp Sells 93,615 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Stock (PFE) Opinions on Market Rotation to Defensives - Quiver Quantitative
Pfizer Inc. $PFE Shares Bought by State of New Jersey Common Pension Fund D - MarketBeat
TCTC Holdings LLC Reduces Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Bought by Aberdeen Group plc - MarketBeat
Public Sector Pension Investment Board Grows Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Assetmark Inc. Buys 193,859 Shares of Pfizer Inc. $PFE - MarketBeat
Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings - Insider Monkey
Pfizer Advances VESPER-5 Obesity and Diabetes Trial, Targeting a Key Growth Market - TipRanks
Fund Update: 753,189 PFIZER (PFE) shares added to THORNBURG INVESTMENT MANAGEMENT INC portfolio - Quiver Quantitative
Pfizer Obesity And Hemophilia Advances Spark Fresh Interest In Valuation - Yahoo Finance
Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds? - Insider Monkey
Pfizer Hemophilia And Obesity Updates Add Context To Valuation Debate - simplywall.st
Versor Investments LP Sells 37,800 Shares of Pfizer Inc. $PFE - MarketBeat
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 - Yahoo Finance
Pfizer (NYSE:PFE) Lowered to "Hold" Rating by Daiwa America - MarketBeat
Pfizer Inc. $PFE Shares Sold by Prospera Financial Services Inc - MarketBeat
Pfizer Inc. $PFE Position Cut by CENTRAL TRUST Co - MarketBeat
Pfizer Inc. $PFE Stake Reduced by GFS Advisors LLC - MarketBeat
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):